Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1967 1
1969 1
1980 1
1982 1
1983 1
1994 2
1995 6
1996 9
1997 16
1998 24
1999 21
2000 32
2001 20
2002 26
2003 32
2004 63
2005 50
2006 46
2007 44
2008 52
2009 65
2010 62
2011 69
2012 83
2013 103
2014 116
2015 151
2016 324
2017 459
2018 518
2019 642
2020 827
2021 1062
2022 85
Text availability
Article attribute
Article type
Publication date

Search Results

4,361 results
Results by year
Filters applied: . Clear all
Page 1
(68)Ga-PSMA PET/CT in prostate cancer.
García Garzón JR, de Arcocha Torres M, Delgado-Bolton R, Ceci F, Alvarez Ruiz S, Orcajo Rincón J, Caresia Aróztegui AP, García Velloso MJ, García Vicente AM; Oncology Task Force of Spanish Society of Nuclear Medicine and Molecular Imaging. García Garzón JR, et al. Rev Esp Med Nucl Imagen Mol (Engl Ed). 2018 Mar-Apr;37(2):130-138. doi: 10.1016/j.remn.2017.07.004. Epub 2017 Sep 21. Rev Esp Med Nucl Imagen Mol (Engl Ed). 2018. PMID: 28941866 Review. English, Spanish.
PSMA is a transmembrane protein present in all prostatic tissues. ...Moreover, the expression level of PSMA has a prognostic value for disease outcome. PET measures the three-dimensional distribution of (68)Ga-PSMA, producing semi-quantitative images that all
PSMA is a transmembrane protein present in all prostatic tissues. ...Moreover, the expression level of PSMA has a prognostic v
PSMA-Targeted Radiopharmaceuticals for Imaging and Therapy.
Wester HJ, Schottelius M. Wester HJ, et al. Semin Nucl Med. 2019 Jul;49(4):302-312. doi: 10.1053/j.semnuclmed.2019.02.008. Epub 2019 Apr 30. Semin Nucl Med. 2019. PMID: 31227053 Review.
Even though monoclonal antibodies were investigated and introduced as first PSMA-targeted probes, the inherent advantage of fast tumour uptake and rapid excretion of small molecules has shifted the research focus during the last decade to low molecular weight inhibitors wi …
Even though monoclonal antibodies were investigated and introduced as first PSMA-targeted probes, the inherent advantage of fast tumo …
PSMA Theranostics: Current Status and Future Directions.
Rahbar K, Afshar-Oromieh A, Jadvar H, Ahmadzadehfar H. Rahbar K, et al. Mol Imaging. 2018 Jan-Dec;17:1536012118776068. doi: 10.1177/1536012118776068. Mol Imaging. 2018. PMID: 29873291 Free PMC article. Review.
There is increasing evidence of encouraging response rates and a low toxicity profile of radioligand therapy (RLT) of metastatic castration-resistant prostate cancer using (177)Lu-labeled PSMA ligands. In this article, we review the current status of diagnostics and therap …
There is increasing evidence of encouraging response rates and a low toxicity profile of radioligand therapy (RLT) of metastatic castration- …
Lutetium (177) PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy.
Emmett L, Willowson K, Violet J, Shin J, Blanksby A, Lee J. Emmett L, et al. J Med Radiat Sci. 2017 Mar;64(1):52-60. doi: 10.1002/jmrs.227. J Med Radiat Sci. 2017. PMID: 28303694 Free PMC article. Review.
Prostate-specific membrane antigen (PSMA) is a receptor on the surface of prostate cancer cells that is revolutionising the way we image and treat men with prostate cancer. ...This targeted therapy for prostate cancer has, to date, predominately used Lutetium 177 (Lu) labe …
Prostate-specific membrane antigen (PSMA) is a receptor on the surface of prostate cancer cells that is revolutionising the way we im …
Review of Gallium-68 PSMA PET/CT Imaging in the Management of Prostate Cancer.
Lenzo NP, Meyrick D, Turner JH. Lenzo NP, et al. Diagnostics (Basel). 2018 Feb 11;8(1):16. doi: 10.3390/diagnostics8010016. Diagnostics (Basel). 2018. PMID: 29439481 Free PMC article. Review.
Over 90% of prostate cancers over-express prostate specific membrane antigen (PSMA) and these tumor cells may be accurately targeted for diagnosis by (68)Ga-PSMA-positron emission tomography/computed tomography ((68)Ga-PSMA-PET/CT) imaging. ...In addition to …
Over 90% of prostate cancers over-express prostate specific membrane antigen (PSMA) and these tumor cells may be accurately targeted …
225Ac-PSMA-617 for PSMA-Targeted alpha-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer.
Kratochwil C, Bruchertseifer F, Giesel FL, Weis M, Verburg FA, Mottaghy F, Kopka K, Apostolidis C, Haberkorn U, Morgenstern A. Kratochwil C, et al. J Nucl Med. 2016 Dec;57(12):1941-1944. doi: 10.2967/jnumed.116.178673. Epub 2016 Jul 7. J Nucl Med. 2016. PMID: 27390158 Free article.
Prostate-specific membrane antigen (PSMA) is a promising target in prostate cancer. Recently, we started the first-in-human treatment with an alpha-radionuclide-labeled PSMA ligand. Although the case series is still ongoing, we here report in advance about two patie …
Prostate-specific membrane antigen (PSMA) is a promising target in prostate cancer. Recently, we started the first-in-human treatment …
Third-line treatment and (177)Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review.
von Eyben FE, Roviello G, Kiljunen T, Uprimny C, Virgolini I, Kairemo K, Joensuu T. von Eyben FE, et al. Eur J Nucl Med Mol Imaging. 2018 Mar;45(3):496-508. doi: 10.1007/s00259-017-3895-x. Epub 2017 Dec 16. Eur J Nucl Med Mol Imaging. 2018. PMID: 29247284 Free PMC article. Review.
RESULTS: Twelve studies including 669 patients reported (177)Lu-PSMA RLT. Overall, 43% of the patients had a maximum decline of PSA of 50% following treatment with (177)Lu-PSMA RLT. The treatment with (177)Lu-PSMA-617 and (177)Lu-PSMA for imaging and t …
RESULTS: Twelve studies including 669 patients reported (177)Lu-PSMA RLT. Overall, 43% of the patients had a maximum decline of PSA o …
Head-to-Head Comparison of (68)Ga-PSMA-11 with (18)F-PSMA-1007 PET/CT in Staging Prostate Cancer Using Histopathology and Immunohistochemical Analysis as a Reference Standard.
Kuten J, Fahoum I, Savin Z, Shamni O, Gitstein G, Hershkovitz D, Mabjeesh NJ, Yossepowitch O, Mishani E, Even-Sapir E. Kuten J, et al. J Nucl Med. 2020 Apr;61(4):527-532. doi: 10.2967/jnumed.119.234187. Epub 2019 Sep 27. J Nucl Med. 2020. PMID: 31562225 Free article.
(18)F-PSMA-1007 is a novel prostate-specific membrane antigen (PSMA)-based radiopharmaceutical for imaging prostate cancer (PCa). ...The Cohen kappa-coefficient was used to assess the concordance between (18)F-PSMA-1007 and (68)Ga-PSMA-11 for detection …
(18)F-PSMA-1007 is a novel prostate-specific membrane antigen (PSMA)-based radiopharmaceutical for imaging prostate cancer (PC …
PSMA expression on neovasculature of solid tumors.
Van de Wiele C, Sathekge M, de Spiegeleer B, De Jonghe PJ, Debruyne PR, Borms M, Beels L, Maes A. Van de Wiele C, et al. Histol Histopathol. 2020 Sep;35(9):919-927. doi: 10.14670/HH-18-215. Epub 2020 Apr 13. Histol Histopathol. 2020. PMID: 32282924 Review.
Similar to the introduction of PSMA-targeting theranostics in prostate carcinoma, overexpression of PSMA on newly formed tumor vessels may serve as a target for imaging and subsequent treatment of cancer through the use of agents that are capable of blocking PSMA
Similar to the introduction of PSMA-targeting theranostics in prostate carcinoma, overexpression of PSMA on newly formed tumor …
[PSMA radioligand therapy in patients with advanced prostate cancer].
Bögemann M, Herrmann K, Radtke JP, Rahbar K. Bögemann M, et al. Urologe A. 2020 Jun;59(6):680-686. doi: 10.1007/s00120-020-01205-w. Urologe A. 2020. PMID: 32333064 Review. German.
OBJECTIVES: Establishment of status quo of (177)Lu-PSMA-RLT in mCRPC in 2020. MATERIALS AND METHODS: Presentation of the therapy landscape in mCRPC and the current evidence on (177)Lu-PSMA-RLT after PubMed based literature search. RESULTS: Several larger retrospecti …
OBJECTIVES: Establishment of status quo of (177)Lu-PSMA-RLT in mCRPC in 2020. MATERIALS AND METHODS: Presentation of the therapy land …
4,361 results